CA1041010A - Process for preparing a curing agent for leukemia - Google Patents
Process for preparing a curing agent for leukemiaInfo
- Publication number
- CA1041010A CA1041010A CA206,606A CA206606A CA1041010A CA 1041010 A CA1041010 A CA 1041010A CA 206606 A CA206606 A CA 206606A CA 1041010 A CA1041010 A CA 1041010A
- Authority
- CA
- Canada
- Prior art keywords
- factor
- sephadex
- emulsion
- supernatant
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 208000032839 leukemia Diseases 0.000 title abstract description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000000839 emulsion Substances 0.000 claims abstract description 27
- 239000006228 supernatant Substances 0.000 claims abstract description 23
- 210000002826 placenta Anatomy 0.000 claims abstract description 18
- 239000000706 filtrate Substances 0.000 claims abstract description 16
- 238000010438 heat treatment Methods 0.000 claims abstract description 16
- 239000012530 fluid Substances 0.000 claims abstract description 15
- 238000009826 distribution Methods 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920002307 Dextran Polymers 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000012528 membrane Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 4
- 238000001816 cooling Methods 0.000 claims abstract description 3
- 238000000227 grinding Methods 0.000 claims abstract description 3
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 3
- 239000002504 physiological saline solution Substances 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 230000007717 exclusion Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 102000008217 Pregnancy Proteins Human genes 0.000 claims description 5
- 108010035746 Pregnancy Proteins Proteins 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 230000002449 erythroblastic effect Effects 0.000 claims description 4
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 229920005654 Sephadex Polymers 0.000 abstract description 33
- 239000012507 Sephadex™ Substances 0.000 abstract description 33
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 abstract description 5
- 239000007863 gel particle Substances 0.000 abstract description 5
- 238000000502 dialysis Methods 0.000 abstract description 4
- 238000004440 column chromatography Methods 0.000 abstract description 3
- 238000005119 centrifugation Methods 0.000 abstract description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000003513 alkali Substances 0.000 abstract 1
- 239000008151 electrolyte solution Substances 0.000 abstract 1
- 239000012847 fine chemical Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000002808 molecular sieve Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 abstract 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 84
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 84
- 230000000694 effects Effects 0.000 description 49
- 239000002609 medium Substances 0.000 description 29
- 238000000605 extraction Methods 0.000 description 26
- 239000000284 extract Substances 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 235000019647 acidic taste Nutrition 0.000 description 16
- 230000003169 placental effect Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000009422 growth inhibiting effect Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 239000000063 antileukemic agent Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 108091005896 globular proteins Proteins 0.000 description 3
- 102000034238 globular proteins Human genes 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 102000018727 5-Aminolevulinate Synthetase Human genes 0.000 description 2
- 108010052384 5-Aminolevulinate Synthetase Proteins 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 239000002535 acidifier Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000719 anti-leukaemic effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 101100238304 Mus musculus Morc1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000130712 Opisthosiphon coloni Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 239000003912 lipotropic agent Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP48096689A JPS5221570B2 (en, 2012) | 1973-08-30 | 1973-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1041010A true CA1041010A (en) | 1978-10-24 |
Family
ID=14171746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA206,606A Expired CA1041010A (en) | 1973-08-30 | 1974-08-08 | Process for preparing a curing agent for leukemia |
Country Status (8)
Country | Link |
---|---|
US (1) | US4054648A (en, 2012) |
JP (1) | JPS5221570B2 (en, 2012) |
CA (1) | CA1041010A (en, 2012) |
CH (1) | CH604723A5 (en, 2012) |
DE (1) | DE2441454C3 (en, 2012) |
FR (1) | FR2242109B1 (en, 2012) |
GB (1) | GB1461335A (en, 2012) |
SE (1) | SE430123B (en, 2012) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH635748A5 (fr) * | 1977-08-16 | 1983-04-29 | Cellorgan Laboratoires Sa | Procede d'obtention de cellules placentaires de brebis. |
FR2507476B1 (fr) * | 1981-06-12 | 1985-08-23 | Cehovic Georges | Procede de preparation de nouvelles substances actives du placenta a usage therapeutique |
US4837157A (en) * | 1982-07-20 | 1989-06-06 | Coventry Health Authority | Sample preparation method for liquid chromatography |
JPS59219235A (ja) * | 1983-05-30 | 1984-12-10 | Mitsui Toatsu Chem Inc | 消化性潰瘍用剤 |
ZA847349B (en) * | 1983-10-05 | 1985-04-24 | Solco Basel Ag | Process for the preparation of a biologically active extract |
IE60059B1 (en) * | 1985-04-19 | 1994-05-18 | Oncogene Science Inc | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
EP0431164A4 (en) * | 1989-04-21 | 1992-06-03 | Kishinevsky Selskokhozyaistvenny Institut Imeni M.V. Frunze | Preparation with an anti-inflammatory, lactogenous and stimulating action, and method of obtaining it |
WO1991000098A1 (en) * | 1989-06-23 | 1991-01-10 | Kishinevsky Selskokhozyaistvenny Institut Imeni M.V.Frunze | Anti-inflammatory preparation and method of obtaining it |
MD838G2 (ro) * | 1992-07-21 | 1998-09-30 | Alexandr Nicolaenco | Remediu biologic activ cu proprietate imunomodulatoare, procedeu de obţinere a lui, preparat pe baza lui şi procedeu de normalizare a stării fiziologice a omului şi animalelor |
RU94022543A (ru) * | 1994-06-10 | 1996-05-20 | АОЗТ "Научно-практический центр медикобиологических проблем" | Основа лекарственного средства и способ ее изготовления |
UA26177C2 (uk) * | 1997-11-13 | 1999-06-07 | Товариство З Обмеженою Відповідальністю "Нір" | Спосіб одержаhhя протизапальhого засобу |
RU2194502C2 (ru) * | 2000-12-27 | 2002-12-20 | Наровлянский Александр Наумович | Иммуномодулятор - метаболик - детоксикант - адаптоген - радиопротектор |
RU2235550C2 (ru) * | 2002-05-14 | 2004-09-10 | Геннадий Гаврилович Шитов | Лекарственное средство бионормализующего действия и способ его получения |
RU2241474C1 (ru) * | 2003-04-14 | 2004-12-10 | Скаткин Михаил Георгиевич | Препарат из плаценты и способ его получения |
RU2237486C1 (ru) * | 2003-08-07 | 2004-10-10 | Закрытое акционерное общество Научно-производственное предприятие "Агрофарм" | Способ получения биологически активных липофильной и гидрофильной фракций плаценты свиной |
WO2007011693A2 (en) * | 2005-07-14 | 2007-01-25 | Medistem Laboratories, Inc. | Compositions of placentally-derived stem cells for the treatment of cancer |
RU2329819C2 (ru) * | 2006-07-25 | 2008-07-27 | ООО "НПФ ВятМедДиа" | Способ получения диагностического реагента тромбопластина полного из плаценты человека |
RU2355405C2 (ru) * | 2007-05-17 | 2009-05-20 | Михаил Аркадьевич Шурдов | Пептидный экстракт плаценты и способ его изготовления |
RU2377250C2 (ru) * | 2007-09-11 | 2009-12-27 | Геннадий Гаврилович Шитов | Модулятор процессов обмена веществ и способ его получения |
RU2434018C2 (ru) * | 2009-12-30 | 2011-11-20 | Государственное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО АГМА Росздрава) | Способ получения и очистки ингибина-а человека |
RU2502515C2 (ru) * | 2012-04-06 | 2013-12-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Волгоградский государственный аграрный университет | Способ получения тканевого лечебного препарата, включающего в себя жидкую функцию из яичника, и маточного содержимого от плодов-телочек |
-
1973
- 1973-08-30 JP JP48096689A patent/JPS5221570B2/ja not_active Expired
-
1974
- 1974-07-31 GB GB3381774A patent/GB1461335A/en not_active Expired
- 1974-08-08 CA CA206,606A patent/CA1041010A/en not_active Expired
- 1974-08-12 US US05/496,814 patent/US4054648A/en not_active Expired - Lifetime
- 1974-08-21 CH CH1140474A patent/CH604723A5/xx not_active IP Right Cessation
- 1974-08-29 SE SE7410972A patent/SE430123B/xx not_active IP Right Cessation
- 1974-08-29 FR FR7429570A patent/FR2242109B1/fr not_active Expired
- 1974-08-29 DE DE2441454A patent/DE2441454C3/de not_active Expired
Also Published As
Publication number | Publication date |
---|---|
JPS5048108A (en, 2012) | 1975-04-30 |
JPS5221570B2 (en, 2012) | 1977-06-11 |
US4054648A (en) | 1977-10-18 |
DE2441454B2 (de) | 1980-12-11 |
CH604723A5 (en, 2012) | 1978-09-15 |
FR2242109B1 (en, 2012) | 1978-07-21 |
FR2242109A1 (en, 2012) | 1975-03-28 |
DE2441454C3 (de) | 1982-01-14 |
SE430123B (sv) | 1983-10-24 |
SE7410972L (en, 2012) | 1975-04-28 |
DE2441454A1 (de) | 1975-03-27 |
GB1461335A (en) | 1977-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1041010A (en) | Process for preparing a curing agent for leukemia | |
CN101332211B (zh) | 一种水蛭提取物及其制备方法与应用 | |
JPS62209101A (ja) | エキナセアプルプレアまたはエキナセアアングステイフオリアの細胞培養物からの免疫刺激作用性ポリサツカライド、その製造方法及びこれを含む製剤 | |
NL8300727A (nl) | Nieuwe glycoproteinen, werkwijzen ter bereiding daarvan alsmede therapeutische anti-tumormiddelen die dergelijke glycoproteinen bevatten. | |
US4843067A (en) | Polysaccharide containing pharmaceutical composition for increasing the immune function | |
CN108530552A (zh) | 昆布多糖的制备及在制备抗肿瘤药物中的应用 | |
CN1857711A (zh) | 脑蛋白水解物及其冻干制剂的生产方法 | |
CA1063019A (en) | Extracts of the haemopoietic system | |
CN107602719B (zh) | 一种具有显著辅助抗肿瘤活性的灵芝子实体精制多糖及其制备方法和应用 | |
CN100475841C (zh) | 注射用胎盘多肽制备方法 | |
CA1324084C (en) | Method of extracting a physiological active substance from the husks of pine nuts and anti-contagion medicine made of said extract as principal raw material | |
CN108864316B (zh) | 一种磺酸化牡丹籽多糖及其制备治疗肝癌辅助药物中的应用 | |
CN1327852C (zh) | 一种具有免疫调节作用的保健食品及其制备方法 | |
CN106478830A (zh) | 一种厚朴花低聚糖及多糖的制备方法 | |
CA2305825A1 (en) | Novel bioactivating substance | |
CN1038512C (zh) | 促肝细胞生长素生产方法 | |
CN101744770B (zh) | 人参多糖注射剂及其制备方法 | |
US3949069A (en) | Nitrogen-containing carbohydrate | |
CN111437248A (zh) | 一种益肠寿口服液及其制备方法与应用 | |
CN118562026B (zh) | 金乌贼墨肽聚糖的制备方法及用途 | |
Revell et al. | Inhibition of macrophage migration by a proteoglycan extracted from Kurloff cells of the guinea-pig | |
JPH0379602A (ja) | 免疫刺激・抗増殖作用を有する多糖類、その製造方法及びこの物質を含有した薬剤 | |
RU2295963C1 (ru) | Способ получения иммуностимулятора | |
JP2714663B2 (ja) | 腸内有益菌増殖促進剤 | |
JPH0314521A (ja) | 抗腫瘍性物質の製造法 |